Mr. Sebastien Plouffe reports

DEFENCE TO CONNECT WITH INDUSTRY LEADERS AND POTENTIAL PARTNERS DURING THE JP MORGAN HEALTHCARE CONFERENCE IN SAN FRANCISCO. PLANS TO EXPAND THE NEXT GENERATION OF RADIO-IMMUNO CONJUGATES IN 2025

Defence Therapeutics Inc. will participate in the Biotech Showcase conference next week in San Francisco during the J.P. Morgan Healthcare Conference to meet with industry leaders, partners and potential investors.

The Biotech Showcase is a premier investor conference committed to creating a platform for biotech companies, offering them a unique opportunity to showcase their innovation and engage one-to-one with investors and biopharmaceuticals executives. The life science conference is taking place from Jan. 13 to Jan. 16 in San Francisco during the JP Morgan Healthcare Conference, which is the premier health care investment symposium attracting thousands of industry leaders and investors.

"Our CSO, Dr. Maxime Parisotto, and I will be actively participating in the health care conference and meetings related in San Francisco to meet with global industry leaders, potential partners and investors to reinforce our network in the U.S. ecosystem and more importantly to clearly demonstrate the strength and importance of our proprietary Accum technology platform in the U.S. life science market. The Accum technology platform has a great potential to play a pivotal role to improve ADCs and in the development of targeted radiopharmaceutical therapies, which we are fully dedicated to expanding in 2025," said Sebastien Plouffe, chief executive officer and president of Defence.

The company is also pleased to announce the closing of the first tranche of its previously announced non-brokered private placement of units of the company at a price of 60 cents per unit for aggregate gross proceeds of $300,000. Each unit consists of one common share in the capital of the company and one common share purchase warrant. Each warrant is exercisable to acquire one additional share at an exercise price of 75 cents per share for a period of 24 months from the date of the closing.

In connection with the closing, the company paid a cash finder's fee of $24,000 and issued 40,000 finder warrants to certain qualified arm's-length finder. Each finder warrant is exercisable into one share at an exercise price of 75 cents per share on or before the warrant expiry date.

The company intends to use the net proceeds of the offering to advance its preclinical and clinical programs and for general working capital. All securities issued in connection with the offering are subject to a statutory hold period of four months plus a day from their date of issue in accordance with applicable securities legislation.

About Defence Therapeutics Inc.

Defence is a publicly traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform in addition to novel immune-oncology vaccines. The core of the Defence platform is the Accum technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.

We seek Safe Harbor.